Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
RootData Transparency Alert: Core Information Missing for Beatcoin, Ink Finance, NXT, and Other Projects

RootData Transparency Alert: Core Information Missing for Beatcoin, Ink Finance, NXT, and Other Projects

ChaincatcherChaincatcher2026/01/26 06:57
Show original

ChainCatcher news, Web3 asset data platform RootData issued a routine transparency alert on Twitter (X), stating that the financing information of projects such as Beatcoin, Ink Finance, NXT, XDC Network, and Eventflo is questionable, and called on project teams to submit/update information on RootData to improve their transparency scores. In addition, RootData stated that it will continue to monitor and expose "black box" projects that lack core information.

It is reported that the RootData transparency score is used to measure the integrity and timeliness of a project, aiming to reflect the project's information disclosure status. The transparency score is divided into five levels from A to F, with a lower score indicating less complete information disclosure, higher risk of misconduct, and requiring investors to be highly vigilant.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage